Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2329–2352 of 3,919 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Prostate Cancer Clear all

Conditions: Adenocarcinoma of the Prostate, Stage IV Prostate Cancer
Interventions: AT-101, Bicalutamide, LHRH agent; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 4
States / cities: Chicago, Illinois • Ann Arbor, Michigan • New Brunswick, New Jersey + 1 more

Conditions: Prostate Adenocarcinoma, Prostate Cancer
Interventions: Flotufolastat F18 PET; Diagnostic Test
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Orange, California

Conditions: Prostate Cancer, Prostate Inflammation, PSA
Interventions: Ibuprofen 400 mg, TID, PSA test; Drug · Diagnostic Test
Lead sponsor: Albany Medical College; Other
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 3
States / cities: Chicago, Illinois • Albany, New York • Hershey, Pennsylvania

Conditions: Breast Cancer, Ovarian Cancer, Pancreas Cancer, Prostate Cancer, BRCA1 Mutation, BRCA-Mutated Ovarian Carcinoma, BRCA-Associated Breast Carcinoma, HRD Positive Advanced Ovarian Cancer
Interventions: TNG348, Olaparib; Drug
Lead sponsor: Tango Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 7
States / cities: Denver, Colorado • Orange City, Florida • Sarasota, Florida + 3 more

Conditions: Prostate Cancer
Interventions: Clomiphene Citrate 25mg; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older · Male only
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2037
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Prostate Cancer
Interventions: dexamethasone, semaxanib; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Male only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 18
States / cities: Duarte, California • Los Angeles, California • Pasadena, California + 13 more

Conditions: Prostate Cancer
Interventions: Explainer video; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 40 Years to 80 Years · Male only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Prostate Cancer
Interventions: Peptide Vaccine, Poly IC-LC; Biological · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Prostate Cancer
Interventions: ODM-201; Drug
Lead sponsor: Orion Corporation, Orion Pharma; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 8
States / cities: Wheat Ridge, Colorado • Norwich, Connecticut • Ocala, Florida + 5 more

Conditions: Prostate Cancer, Castrate Resistant Prostate Cancer
Interventions: sipuleucel-T, ipilimumab; Drug
Lead sponsor: Prostate Oncology Specialists, Inc.; Other
Eligibility: 18 Years and older · Male only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Marina del Rey, California

Conditions: Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions: Biopsy Procedure, Computed Tomography, Electronic Health Record Review, Magnetic Resonance Imaging, MRI-guided Stereotactic Body Radiation Therapy, Questionnaire Administration; Procedure · Other · Radiation
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Irvine, California

Conditions: Prostate Cancer
Interventions: Cabazitaxel XRP6258, Abiraterone acetate, Prednisone 5 mg; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: San Francisco, California • New Haven, Connecticut

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: University of Miami; Other
Eligibility: 30 Years and older · Male only
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2032
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Prostate Cancer
Interventions: myocardial PET imaging; Device
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 51 Years and older · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prostate Cancer
Interventions: bevacizumab, prostatic acid phosphatase-sargramostim fusion protein, sipuleucel-T, therapeutic autologous dendritic cells, in vitro-treated peripheral blood stem cell transplantation; Biological · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Prostate Cancer
Interventions: BNT112, Cemiplimab; Biological · Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 5
States / cities: Tucson, Arizona • Miami, Florida • Pittsburgh, Pennsylvania + 2 more

Conditions: Prostate Cancer
Interventions: sipuleucel-T, DNA Vaccine; Biological
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Prostate Cancer Patients, Non-castrate Prostate Cancer, Recurrent Prostate Cancer, Oligometastatic Prostate Cancer (OMPC)
Interventions: pTVG-HP DNA vaccine, Anti-PD-1 monoclonal antibody; Biological · Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Male only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Prostate Cancer
Interventions: CT-2584, chemotherapy; Drug
Lead sponsor: CTI BioPharma; Industry
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2005
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • New Orleans, Louisiana + 4 more

Conditions: Female Breast Cancer, Prostate Cancer, Colorectal Carcinoma
Interventions: Culturally adapted Online Genetic Counseling and Testing Information; Behavioral
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 20 Years to 79 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Prostate Cancer
Interventions: F-fluorodeoxyglucose positron emission tomography (FDG PET), prostate-specific membrane antigen positron emission tomography (PSMA PET); Diagnostic Test
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Castration Resistant Metastatic Prostate Cancer
Interventions: Testosterone cypionate, Enzalutamide, Testosterone enanthate; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 90 Years · Male only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 6
States / cities: San Diego, California • Baltimore, Maryland • Boston, Massachusetts + 3 more

Conditions: Prostate Cancer (Adenocarcinoma), Prostate Cancer (Diagnosis), Prostate Cancer Metastatic Disease
Interventions: PSMA PET/CT scan; Radiation
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Male only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Interventions: Furosemide, F18-rhPSMA-7.3, Positron Emission Tomography, Computed Tomography; Drug · Other · Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Atlanta, Georgia • Johns Creek, Georgia

Search by objective public record fields.

R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

Utilization of Flotufolastat 18F PET for Post-Focal Therapy Prostate Cancer Evaluation

Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test

Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

HRT-PC Trial: Hormone Recovery After Treatment for Prostate Cancer Trial. An Open-label Phase II Study of Clomiphene Citrate in Patients With Persistent Hypogonadism After ADT for Treatment of Localized Prostate Cancer

SU5416 Compared to Dexamethasone in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy

Surveillance or Focal Therapy

PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment

Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer

Magnetic Resonance-Guided Stereotactic Body Radiation Therapy for the Treatment of Prostate Cancer

Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer

Collection and Measurement of Biomarkers in Prostate Cancer Radiotherapy Patients

Pilot Cohort Study of Rb-82 Myocardial PET Imaging to Evaluate Coronary Microvascular Dysfunction in Men With Prostate Cancer Receiving Androgen-Deprivation Therapy

APC8015 and Bevacizumab in Treating Patients With Prostate Cancer

PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)

Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer

Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC

CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy

Culturally Adapting an Intervention to Increase Genetic Testing in African American Cancer Survivors

PET/CT Characterization of Treatment Resistance

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

PSMA PET for Surveillance After Focal Therapy

Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer